Medicilon(SH:688202) Xin Lang Cai Jing·2025-10-20 02:59Group 1 - The core point of the news is that Meidisi's stock price increased by 5.2% to 63.97 CNY per share, with a trading volume of 166 million CNY and a market capitalization of 8.595 billion CNY as of the report date [1] - Meidisi, established on February 2, 2004, and listed on November 5, 2019, is located in the Pudong New Area of Shanghai and specializes in providing comprehensive new drug research and development services for pharmaceutical companies and other new drug research institutions [1] - The company's main business revenue composition includes 50.34% from preclinical research, 49.64% from drug discovery and pharmaceutical research, and 0.01% from other supplementary services [1] Group 2 - From the perspective of fund holdings, one fund under the Fortune Fund has a significant position in Meidisi, specifically the Fortune SSE Index ETF Link A/B (100053), which held 400 shares in the second quarter, unchanged from the previous period, representing 0.0002% of the circulating shares [2] - The Fortune SSE Index ETF Link A/B (100053) was established on January 30, 2011, with a latest scale of 274 million CNY, and has achieved a year-to-date return of 15.79%, ranking 2944 out of 4218 in its category [2] - The fund managers, Wang Baohe and Fang Min, have tenures of 14 years and 10 years respectively, with Wang managing assets totaling 9.06 billion CNY and Fang managing 25.209 billion CNY [2]